Bradley Pharmaceuticals Launches ROSULA(R) CLK(TM)
26 Novembre 2007 - 1:45PM
PR Newswire (US)
FAIRFIELD, N.J., Nov. 26 /PRNewswire-FirstCall/ -- Bradley
Pharmaceuticals, Inc. (NYSE:BDY) today announced that its Doak
Dermatologics subsidiary has launched ROSULA(R) CLK(TM), a kit
combining two topical skincare products currently marketed by Doak.
The kit contains ROSULA(R) Clarifying Wash(TM) (Sodium
Sulfacetamide 10% and Sulfur 4%) in a urea vehicle, and A-FIL(R)
Cream (meradimate 5% and titanium dioxide 5%) sunscreen. The
ROSULA(R) CLK(TM) kit is available by prescription only. ROSULA(R)
Clarifying Wash(TM), a cleanser offered in an elegant formulation
and large size, is indicated for the treatment of acne vulgaris,
acne rosacea and seborrheic dermatitis. The product was launched by
Doak in June of this year. A-FIL(R) Cream is an opaque SPF-25 dual
barrier sunscreen that reflects and absorbs ultraviolet rays. "The
American Academy of Dermatology* advises patients who suffer from
acne vulgaris and acne rosacea to protect their skin using a
broad-spectrum sunscreen with an SPF of 15 or higher," stated
Daniel Glassman, President and CEO of Bradley Pharmaceuticals. "We
feel that the combination of ROSULA(R) Clarifying Wash(TM) and
A-FIL(R) brand sunscreen will allow patients to more easily follow
this important treatment and skin care regimen and enhances patient
care." Important Product Safety Information About ROSULA(R)
Clarifying Wash(TM): ROSULA(R) Clarifying Wash(TM) is
contraindicated in persons with known or suspected hypersensitivity
to sulfonamides or sulfur. ROSULA(R) Clarifying Wash(TM) is not to
be used by patients with kidney disease. Although rare, topical
sodium sulfacetamide may cause local irritation. For additional
important information about ROSULA(R) CLK(TM) please view full
prescribing information at http://www.bradpharm.com/ or request
full prescribing information by contacting Bradley Pharmaceuticals
at 973-882-1505. Please visit Bradley Pharmaceuticals web site at:
http://www.bradpharm.com/. About Bradley Pharmaceuticals, Inc.
Bradley Pharmaceuticals, Inc. was founded in 1985 as a specialty
pharmaceutical company and markets to niche physician specialties
in the U.S. and international markets. Bradley's success is based
upon its core strengths in marketing and sales, which enable the
company to Commercialize brands that fill unmet patient and
physician needs; Develop new products through life cycle
management; and In-License phase II and phase III drugs with
long-term intellectual property protection that upon approval
leverage Bradley's marketing and sales expertise to increase
shareholder value. Bradley Pharmaceuticals is comprised of Doak
Dermatologics, specializing in therapies for dermatology and
podiatry; Kenwood Therapeutics, providing gastroenterology, OB/GYN,
respiratory and other internal medicine brands; and A. Aarons,
which markets authorized generic versions of Doak and Kenwood
therapies. *Source American Academy of Dermatology website Safe
Harbor for Forward-Looking Statements: This press release contains
"forward-looking statements" within the meaning of the Private
Securities Litigation Reform Act of 1995. Forward- looking
statements include statements that address activities, events or
developments that Bradley expects, believes or anticipates will or
may occur in the future. Forward-looking statements are subject to
numerous risks and uncertainties, many of which are beyond
Bradley's control. Actual results may differ materially from those
projected. These risks and uncertainties include those described
from time to time in Bradley's SEC filings, including its Annual
Report on Form 10-K and its most recent Quarterly Report on Form
10-Q. Except as required by law, Bradley undertakes no obligation
to publicly update any forward-looking statement in this press
release, whether as a result of new information, future events or
otherwise. DATASOURCE: Bradley Pharmaceuticals, Inc. CONTACT:
Investor & Public Relations, Cecelia C. Heer of Bradley
Pharmaceuticals, Inc., +1-973-882-1505, ext. 252, Web site:
http://www.bradpharm.com/
Copyright
Bradley (NYSE:BDY)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Bradley (NYSE:BDY)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024
Real-Time news about Bradley Pharmaceuticals (New York Stock Exchange): 0 recent articles
Plus d'articles sur Bradley Pharmactcl